Unibest
← Back to patent-cliff list

Nefextinib hemifumarate

Tier C — Watch / trade

Nefextinib hemifumarate

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:FGFRs, FLT3

Indications (approved):Solid tumour, Colorectal cancer, Myelodysplastic syndrome, Acute myeloid leukaemia, Idiopathic pulmonary fibrosis, Metastatic cancer, 食管胃结合部肿瘤, Gastric cancer

Regional status

US
-
EU
-
China
Phase II
2021-09-16
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield 22 mg (MAX-40279)
MAX-402792070931-57-4MAX-40279-00135265-82-8MAX-40279-00276872-68-9MAX-40279-0032033057-21-3MAX-40279-0042033057-22-4MAX-40279-005179899-07-1MAX-40279-0062033057-23-5MAX-40279-0071029413-55-5MAX-40279-0082070932-03-3MAX-40279-0092075-46-9MAX-40279-010109384-19-2MAX-40279-0111201916-87-1API · Nefextinib hemifumarate
CodeCAS No.Intermediate
MAX-402792070931-57-4-
MAX-40279-00135265-82-82,4-dichloro-6-methylthieno[3,2-d]pyrimidine
MAX-40279-00276872-68-92-chloro-6-methyl-3,4-dihydrothieno[3,2-d]pyrimidine
MAX-40279-0032033057-21-32-chloro-6-methylthieno[3,2-d]pyrimidine
MAX-40279-0042033057-22-42-chloro-7-iodo-6-methylthieno[3,2-d]pyrimidine
MAX-40279-005179899-07-1(4-fluoro-2-methoxyphenyl)boronic acid
MAX-40279-0062033057-23-52-chloro-7-(4-fluoro-2-methoxyphenyl)-6-methylthieno[3,2-d]pyrimidine
MAX-40279-0071029413-55-5tert-butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate
MAX-40279-0082070932-03-3tert-butyl 4-(4-((7-(4-fluoro-2-methoxyphenyl)-6-methylthieno[3,2-d]pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate
MAX-40279-0092075-46-94-nitro-1H-pyrazole
MAX-40279-010109384-19-2Availabletert-butyl 4-hydroxypiperidine-1-carboxylate
MAX-40279-0111201916-87-1tert-butyl 4-(4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate

Frequently asked questions

What are the approved indications of Nefextinib hemifumarate?

Approved indications include: Solid tumour, Colorectal cancer, Myelodysplastic syndrome, Acute myeloid leukaemia, Idiopathic pulmonary fibrosis, Metastatic cancer, 食管胃结合部肿瘤, Gastric cancer.

When does the Nefextinib hemifumarate patent expire?

No public expiry year is available for Nefextinib hemifumarate yet; this page updates once verified.

How many synthesis routes are recorded for Nefextinib hemifumarate?

1 synthesis routes are recorded; the shortest is 8 steps with 22 mg (MAX-40279) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Nefextinib hemifumarate intermediates?

1 intermediate CAS of Nefextinib hemifumarate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Nefextinib hemifumarate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-06